COVID-19 pandemic is raging through the entire world. Initial days were terrible by way of the clinical community anywhere in the world having no answer to the viral pathology. Gradually the clinical community, initially in Italy and later on across Europe and USA resorted to extensive autopsy studies. These were the learning steps as for the viral particle, its entry, its propagation, its final place of settlement, its affection of different tissues leading to the clinical signs and symptoms. Essence of learning gave us the following information;
a. the virus is a designer virus unlike all other viruses and affects nearly all organs and tissues – resulting in cerebral stroke, cardiac muscle affection, in vivo coagulation, renal affection, so on.
b. the final learning was very interesting – inflammatory response was one of the primary expressions, which we could manage through steroidal anti-inflammatory effects.
c. another emerging point was extensive intravascular coagulation, which could be managed by therapeutic interventions like aspirin as well as anti-factor X.
d. what stands still as an unanswered question is – why and how comorbidities like diabetes, hypertension, malignancy, etc. take some of the cases through uncontrolled expressions of inflammation and coagulation.
Requirements:
a. diagnostics – primary host organ lungs can easily be scanned for earliest presentation of consolidation by now. There are further improvements coming. Inflammatory markers like IL-6, ferritin, as well as IL-8, etc. have already come in clinical usage.
b. therapeutics – as mentioned profound anti-inflammatory as well as anticoagulation agents are apparently the answer till this point.
c. prevention – unanswered portion of this pandemic now gets confined to the population with comorbidities, resulting in ongoing casualties.
This product looks at immobilizing the viral particle on the nasal epithelium through a formulation of natural amino acid L-lysine and its oligomer. The molecule lysine and its oligomer have exposed positive and negative charged centers which are possibly doing hydrogen bonding (a particular type of binding) with the exposed amino acids of microbes as well as viral particle. Using in silico methods, we are exploring the mode of binding behavior of lysine and its oligomer with the proteins of COVID-19 (ACE2) and phospholipids of microbes and viral particles. Phospholipid binding behavior will give additional mileage to this formulation in prevention of upper respiratory tract infections in children and adults in addition to COVID-19.This formulation has also showed antimicrobial properties against microbes including Staphylococcus aureus, but nontoxic to mammalian cells.
Chief Guest –Dr. Bhabatosh Biswas, Chairman, Board of Governors, NIPER Kolkata
Spokespersons:
Speaking –Dr. V. Ravichandiran, DIRECTOR, NIPER Kolkata
Mr. Mihir Sarkar, MD, Diamond Drug Pvt. Ltd. Kolkata
Speaking –Dr. Debatosh Datta, Ex-Professor, IIT Bombay, IIT Patna, Consultant Apollo Hospital, Kolkata, R&D-Head Diamond Drugs Private Limited.
Speaking –Dr. Somasundaram Arumugam, Asst. Professor, NIPER Kolkata
Speaking –Dr. Utpal Mohan, Asst. Professor, NIPER Kolkata
Speaking –Dr. Devendra K. Dhaked, Asst. Professor, NIPER Kolkata
Dr. Soumi Sukla, Veterinarian, NIPER Kolkata
Dr. Pallab Datta, Asst. Professor, NIPER Kolkata
Online –Prof. NK Ganguly, Chairman, AHERF, Apollo Delhi
Facebook Comments